Elicera Therapeutics AB (publ) (FRA:8E8)

Elicera Therapeutics AB Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	26	23	5	8	6	10
Market Cap Growth	143.52%	357.71%	-36.97%	30.01%	-35.37%	-
Enterprise Value	23	20	2	6	3	4
Last Close Price	0.51	0.47	0.12	0.41	0.29	0.47
PS Ratio	25.60	23.34	8.22	8.03	54.32	169174.86
PB Ratio	11.90	10.85	2.82	5.50	2.12	1.90
P/TBV Ratio	11.90	10.85	2.82	5.50	2.12	1.90
EV/Sales Ratio	22.97	20.12	3.92	5.73	24.39	78418.50
Net Debt / Equity Ratio	-1.06	-1.06	-1.27	-1.79	-1.34	-1.00
Net Debt / EBITDA Ratio	1.39	1.39	1.57	1.72	2.27	4.00
Asset Turnover	0.40	0.40	0.25	0.29	0.03	0
Quick Ratio	6.75	6.75	4.01	2.16	3.27	21.04
Current Ratio	6.75	6.75	4.06	2.19	3.39	21.68
Return on Equity (ROE)	-78.89%	-78.89%	-86.68%	-66.66%	-45.72%	-42.00%
Return on Assets (ROA)	-40.79%	-40.79%	-36.55%	-27.94%	-23.95%	-24.36%
Return on Capital Employed (ROCE)	-76.80%	-76.80%	-81.30%	-104.20%	-59.00%	-25.10%
Earnings Yield	-6.26%	-6.87%	-27.49%	-18.18%	-27.96%	-13.21%
Buyback Yield / Dilution	-44.30%	-44.30%	-59.89%	0.40%	-23.97%	-32.98%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.